DRUG STUDY Patients Name: C.R.

Drug: Mupirocin Ointment

DRUG Generic name: Mupirocin Brand name: Bactroban Classification: Anti-infectives Dose: N/A Frequency: TID Form: Ointment Route: Topical INDICATION Infected traumatic skin lesions ACTION Inhibits bacterial protein and RNA synthesis by reversibly and specifically, binding to bacterial isoleucyltransfer RNA synthase, bactericidal.

Age: 24y/o Diagnosis: Potts Disease

CONTRAINDICATION Hypersensitivity to drug and its components, moderate/ severe renal impairment. ADVERSE REACTIONS Mouth and lip sores, dry skin, rash, redness, stinging or pain, secondary wound infection. NUSRING RESPONSIBILITIES Assessed patients condition. Instructed SO to wash affected area with soap and water and dry it thoroughly, then apply small amount of drug to area and rub it gently, and apply gauze and dressing. Advised patient to complete entire course of therapy even if symptoms disappear, and try not to miss doses. Advised patient to report if skin infection doesnt improve within 3-5 days or if it worsens. Cautioned patient not to apply drug to eye or mucus membrane.

DRUG STUDY Patients Name: C.R. Drug: Ciprofloxacin Hydrochloride

DRUG Generic name: Ciprofloxacin Hydrochloride Brand name: Ciloxan Classification: Anti-infectives, flouroquinolone Dose: 500mg Frequency: BID Form: Tab Route: PO INDICATION Respiratory, urinary, gastrointestinal, bone, joint, skin, and soft tissue infections ACTION Bactericidal inhibits DNA enzyme that interferes with replication; considered broad spectrum, is not useful against anaerobic infections. CONTRAINDICATION Contraindicated in patients hypersensitive to drug or other fluoroquinolone antibiotics

Age: 24y/o Diagnosis: Potts Disease

ADVERSE REACTIONS CNS: nausea, dizziness, headache, restlessness EENT: local burning or discomfort, white crystalline precipitate in superficial portion of corneal defect in patients with corneal ulcers, margin crusting, crystals or scales, foreign body sensation, itching, conjunctival hyperemia, allergic reactions GI: bad or bitter taste in mouth, vomiting, diarrhea, abdominal pain NUSRING RESPONSIBILITIES Assessed patients condition. Watched out for signs and symptoms of serious adverse effects including GI problems, jaundice, tendon problems and hypersensitivity reactions. Instructed client to avoid antacids, iron supplements, and milk and diary products for atleast 2 hours after taking medication. Instructed client to report any tendon pain or inflammation. Encouraged adequate fluid intake, 6 to 8 glasses daily to ensure adequate hydration.

DRUG STUDY Patients Name: C.R. Drug: Tramadol Hydrochloride

DRUG Generic name: Tramadol Hydrochloride Brand name: Ultram, Dromadol Classification: Analgesic Dose: 50mg Frequency : PRN Form: ampule Route: IV INDICATION ACTION A centrally acting synthetic analgesic compound not chemically related to opioids. Thought to bind to opioid receptors and inhibit reuptake of norepinephrine and serotonin. CONTRAINDICATION

Age: 24y/o Diagnosis: Potts Disease

ADVERSE REACTIONS CNS: dizziness, Contraindicated in vertigo, headache, patients hypersensitive to drug or other opioids, somnolence, CNS stimulation, asthenia, in those with acute anxiety, confusion, intoxication from coordination alcohol, hypnotics, disturbance, euphoria, centrally acting nervousness, sleep analgesics, opioids, or disorder, seizures, psychotropic drugs. malaise CV: vasodilation Serious hypersensitivity EENT: visual disturbances reactions can occur, GI: nausea, usually after the first constipation, vomiting, dose. Patients with dyspepsia, dry mouth, history of anaphylactic diarrhea, abdominal reaction to codeine and pain, anorexia, other opioids may be at flatulence increased risk. GU: urine retention, urinary frequency, Use cautiously in patients menopausal NUSRING RESPONSIBILITIES Assessed patients condition. Reassessed patients level of pain at least 30 minutes after administration. Monitored CV and respiratory status. Withhold dose and notify physician if respirations decrease or rate is below 12breaths/min. For better analgesic effect, give drug before onset of intense pain. Monitor patients at risk for seizures. Drug may reduce

Moderate to
moderately severe pain

at risk for seizures or respiratory depression; in patients with increased intracranial pressure or head injury, acute abdominal conditions, or renal or hepatic impairment; or in patients with physical dependence on opioids.

symptoms, proteinuria Musculoskeletal: hypertonia Respiratory: respiratory depression Skin: pruritus, diaphoresis, rash

seizure threshold. Monitored patient for drug dependence. Drug can produce dependence similar to that of codeine or dextropropoxyphene and thus has potential for abuse. Instructed patient to report any signs and symptoms of hypersensitivity reactions and adverse reactions.